Which agent lowers LDL-C by inhibiting ATP citrate lyase?

Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

Multiple Choice

Which agent lowers LDL-C by inhibiting ATP citrate lyase?

Blocking ATP citrate lyase in the liver reduces the production of acetyl-CoA needed for cholesterol synthesis, which lowers hepatic cholesterol content. In response, the liver increases LDL receptor expression, pulling more LDL particles out of the bloodstream and lowering LDL-C. Bempedoic acid is a prodrug activated in the liver that inhibits ACLY, producing this cholesterol-lowering effect. The other agents work through different pathways: nicotinic acid mainly reduces VLDL production and alters HDL, ezetimibe blocks intestinal cholesterol absorption, and cholestyramine binds bile acids to force more cholesterol turnover.

Blocking ATP citrate lyase in the liver reduces the production of acetyl-CoA needed for cholesterol synthesis, which lowers hepatic cholesterol content. In response, the liver increases LDL receptor expression, pulling more LDL particles out of the bloodstream and lowering LDL-C.

Bempedoic acid is a prodrug activated in the liver that inhibits ACLY, producing this cholesterol-lowering effect. The other agents work through different pathways: nicotinic acid mainly reduces VLDL production and alters HDL, ezetimibe blocks intestinal cholesterol absorption, and cholestyramine binds bile acids to force more cholesterol turnover.

More practice questions